BMO Raises Novo Nordisk A/S (NVO) Price Target but Flags Prescription Pressures

Novo Nordisk A/S (NYSE:NVO) is among the most profitable healthcare stocks to buy. On January 26, BMO Capital lifted the price target on Novo Nordisk A/S (NYSE:NVO) to $57 from $47 and maintained a Market Perform rating. The firm highlighted flat prescription trends (TRx) for the company’s weight loss candidate Wegovy in the fourth quarter of 2025 relative to the third quarter.

BMO Capital reduced its 2025 Wegovy sales estimate to DKK 77.8 billion, down from DKK 79.8 billion, compared with a consensus forecast of DKK 78.4 billion. Despite favorable tailwinds, including the CVS exclusivity agreement, pressures like the anticipated QoQ pricing continue to exist, the firm noted. That said, BMO Capital estimates a relatively flat 2026 U.S. prescription volume compared with 2025 levels, which would lead to negative YoY U.S. net sales growth.

Three days earlier, Reuters reported that the company’s Wegovy drug was prescribed over 18,000 times in the U.S. during the first full week following its launch. The report cited James Gordon from Barclays, who said,

“The early oral Wegovy launch data is very strong, albeit in a now far better established obesity market versus building the obesity market.”

Novo Nordisk A/S (NYSE:NVO) is a Denmark-based company that specializes in pharmaceutical products. Founded in 1923, the giant operates through two segments: Diabetes and Obesity Care and Rare Disease.

While we acknowledge the potential of NVO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.

Disclosure: None.